Surien Omchit, Masre Siti Fathiah, Basri Dayang Fredalina, Ghazali Ahmad Rohi
Center for Toxicology and Health Risk Studies (CORE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur 50300, Malaysia.
Centre for Diagnostic, Therapeutic & Investigative Studies (CODTIS), Faculty of Health Sciences, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur 50300, Malaysia.
Biomedicines. 2022 Oct 28;10(11):2743. doi: 10.3390/biomedicines10112743.
Skin squamous cell carcinoma (SCC) is a type of non-melanoma skin cancer. Pterostilbene is a natural compound proven to exhibit various pharmacological properties, including chemo-preventive effects. This study aimed to explore the chemo-preventive effect of oral pterostilbene during initiation, promotion or continuous on multistage skin SCC mouse models induced by 7,12-Dimethylbenz(a)anthracene (DMBA)/12-O-Tetradecanoylphorbol-13-acetate (TPA). The experimental design consists of five groups of female Institute of Cancer Research (ICR) mice, with two control groups of vehicle and cancer. Three oral pterostilbene groups consisted of orally administered pterostilbene during initiation, promotion, or continuously. Oral pterostilbene significantly reduced the number and volume of tumours. Oral pterostilbene demonstrated less severe skin histology changes compared to the cancer control group, with less pleomorphic in the cells and nuclei, and the basement membrane remained intact. Our results showed fewer invasive tumours in oral PT-treated groups than in cancer groups that displayed mitotic bodies, highly pleomorphic cells and nuclei, and basement membrane invasion. The cell proliferation marker (Ki-67) was reduced in oral pterostilbene-treated groups. Overall, oral pterostilbene is a promising chemo-preventive intervention due to its anti-initiation and anti-promotion on skin carcinogenesis. Thus, the potential molecular mechanisms of oral pterostilbene chemo-prevention agent should be explored.
皮肤鳞状细胞癌（SCC）是一种非黑色素瘤皮肤癌。紫檀芪是一种天然化合物，已被证明具有多种药理特性，包括化学预防作用。本研究旨在探讨口服紫檀芪在由7,12-二甲基苯并(a)蒽（DMBA）/12-O-十四酰佛波醇-13-乙酸酯（TPA）诱导的多阶段皮肤SCC小鼠模型的起始、促进或持续阶段的化学预防作用。实验设计包括五组雌性癌症研究所（ICR）小鼠，两组对照组分别为赋形剂对照组和癌症对照组。三个口服紫檀芪组分别在起始、促进或持续阶段口服紫檀芪。口服紫檀芪显著减少了肿瘤的数量和体积。与癌症对照组相比，口服紫檀芪的皮肤组织学变化较轻，细胞和细胞核的多形性较小，基底膜保持完整。我们的结果显示，口服PT治疗组的侵袭性肿瘤比显示有丝分裂体、高度多形性细胞和细胞核以及基底膜侵袭的癌症组少。口服紫檀芪治疗组的细胞增殖标志物（Ki-67）减少。总体而言，口服紫檀芪因其对皮肤致癌作用的抗起始和抗促进作用而有望成为一种化学预防干预措施。因此，应探索口服紫檀芪化学预防剂的潜在分子机制。
